The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(5):541–565. doi:10.6004/jnccn.2021.0022
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187–1195. doi:10.1016/j.jhep.2015.02.010
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer. 2018;7:235–260. doi:10.1159/000488035
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–1501. doi:10.1136/gutjnl-2019-318934
   PubMed Web of Science ®Google Scholar
• Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with advanced hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, Phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:565–575. doi:10.1016/S2468-1253(17)30156-5
   PubMed Web of Science ®Google Scholar
• Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology. 2014;60:1697–1707. doi:10.1002/hep.27290
   PubMed Web of Science ®Google Scholar
• Kudo M, Cheng A-L, Park J-W, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with advanced hepatocellular carcinoma (Oriental): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol. 2018;3:37–46. doi:10.1016/S2468-1253(17)30290-X
   PubMed Web of Science ®Google Scholar
• Kudo M. Combination cancer immunotherapy in hepatocellular carcinoma. Liver Cancer. 2018;7(1):20–2711. doi:10.1159/000486487
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a nonrandomised, open-label Phase 2 trial. Lancet Oncol. 2018;19:940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Yang XG, Sun YY, Wang HQ, et al. Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: a propensity score matching analysis. Front Oncol. 2022;13(12):914385. doi:10.3389/fonc.2022.914385
   Google Scholar
• Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30(5):v874–v875. doi:10.1093/annonc/mdz394.029
   Google Scholar
• Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991–1001. doi:10.1016/S1470-2045(21)00151-0
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Jiang JF, Lao YC, Yuan BH, et al. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget. 2017;8:33911–33921. doi:10.18632/oncotarget.15411
   PubMedGoogle Scholar
• Rizzo A, Ricci AD, Brandi G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncol. 2021;17(7):755–757. doi:10.2217/fon-2020-0986
   PubMed Web of Science ®Google Scholar
• Esagian SM, Kakos CD, Giorgakis E, Burdine L, Barreto JC, Mavros MN. Adjuvant transarterial chemoembolization following curative-intent hepatectomy versus hepatectomy alone for hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials. Cancers. 2021;13(12):2984. doi:10.3390/cancers13122984
   PubMed Web of Science ®Google Scholar
• Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (rescue): a nonrandomized, open-label, phase II trial. Clin Cancer Res. 2021;27(4):1003–1011. doi:10.1158/1078-0432.CCR-20-2571
   PubMed Web of Science ®Google Scholar
• Wei F, Huang Q, He J, Luo L, Zeng Y. Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: a short-term prognostic study. Cancer Manag Res. 2021;13:4233–4240. doi:10.2147/CMAR.S304820
   PubMed Web of Science ®Google Scholar
• Liu Q, You N, Li J, et al. Camrelizumab plus sorafenib versus sorafenib monotherapy for advanced hepatocellular carcinoma: a retrospective analysis. Front Oncol. 2021;11:694409. doi:10.3389/fonc.2021.694409
   PubMed Web of Science ®Google Scholar